Celgene Second Quarter Earnings on the Horizon
S&P 500 (NYSE:SPY) component Celgene (NASDAQ:CELG) will unveil its latest earnings tomorrow, Thursday, July 26, 2012. Celgene is a biopharmaceutical company that develops innovative therapies to treat cancer and immune-inflammatory related diseases.
Celgene Earnings Preview Cheat Sheet
Wall St. Earnings Expectations: The average estimate of analysts is for profit of $1.06 per share, a rise of 35.9% from the company’s actual earnings for the same quarter a year ago. The average estimate is the same as three months ago. Between one and three months ago, the average estimate moved up. It has dropped from $1.07 during the last month. Analysts are projecting profit to rise by 26.8% versus last year to $4.35.
Past Earnings Performance: The company missed estimates last quarter after beating forecasts in the prior two. In the first quarter, the company reported net income of 99 cents per share versus a mean estimate of profit of $1.02 per share. In the fourth quarter of the last fiscal year, the company beat estimates by 2 cents.
Investing Insights: Is TV the Next Bullish Catalyst for Apple’s Stock?
A Look Back: In the first quarter, profit rose 57.1% to $401.5 million (90 cents a share) from $255.6 million (54 cents a share) the year earlier, but fell short analyst expectations. Revenue rose 13.2% to $1.27 billion from $1.13 billion.
Stock Price Performance: Between April 25, 2012 and July 24, 2012, the stock price fell $13.35 (-17.26%), from $77.35 to $64. The stock price saw one of its best stretches over the last year between December 14, 2011 and December 27, 2011, when shares rose for nine straight days, increasing 7.9% (+$4.98) over that span. It saw one of its worst periods between April 27, 2012 and May 4, 2012 when shares fell for six straight days, dropping 4.9% (-$3.57) over that span.
Wall St. Revenue Expectations: Analysts predict a rise of 14.4% in revenue from the year-earlier quarter to $1.35 billion.
The company enters this earnings announcement with substantial revenue momentum. The company has averaged year-over-year revenue growth of 27.3% over the last four quarters.
After experiencing income increases the last three quarters, the company is hoping to keep the good news coming with this earnings announcement. Net income rose 32.7% in the third quarter of the last fiscal year and 95.7% in the fourth quarter of the last fiscal year before increasing again in the first quarter.
Analyst Ratings: With 22 analysts rating the stock a buy, none rating it a sell and three rating the stock a hold, there are indications of a bullish stance by analysts.
Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute — click here and get our CHEAT SHEET stock picks now.
(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)
Don’t Miss These Hot Additional Stories: